All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
MPL W515 mutations, CALR exon 9 mutations, and the most frequent mutation observed in MPN, JAK2 V617F, which results in ligand-independent proliferation, are all considered to be key driver mutations of MPN pathogenesis. The term ‘triple-negative’ refers to the absence of mutations in three key driver genes, JAK2, CALR, or MPL. However, patients with triple-negative MPN can carry mutations in other genes.